

A
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
Mortality Through 60 Days
REM 48.2% (53/110) vs Control 53.3% (57/107)
HR: 0.857; 95% CI (0.589, 1.246), p=0.418
Log Rank p-value = 0.423
+ Censored
Control 107 101 76 61 53 50 50
MSC 110 102 81 70 64 59 55
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC




B
All Per Protocol Patients
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All PP Patients (n=155)
REM 49.4% (38/77) vs Control 60.3% (47/78)
HR: 0.719; 95% CI (0.469, 1.103), p=0.1308
Log Rank p-value = 0.131
+ Censored
Control 78 73 53 40 34 31 31
MSC 77 73 58 49 45 41 38
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

**FIGURE 1**


A
REM vs Ctl ITT Patients < 65 Years
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All ITT Patients < 65 yrs (n=125)
REM 25.9% (15/58) vs Control 42% (28/67)
HR: 0.536; 95% CI (0.286, 1.005), p=0.051
Log Rank p-value = 0.0484
+ Censored
Control 67 63 52 45 40 39 39
MSC 58 56 53 48 46 43 42
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC



B
REM vs Ctl ITT Patients ≥ 65 Years
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
Control
MSC
All ITT Patients ≥65 yrs (n=97)
REM 72.2% (39/54) vs Control 69.8% (30/43)
Log Rank p-value = 0.791
+ Censored
Control 43 40 26 18 15 13 13
MSC 54 48 30 24 19 17 15
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

**FIGURE 2**




A
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
Mortality Through 60 Days
REM 26% (15/57) vs Control 42% (28/66)
HR: 0.536; 95% CI (0.286, 1.005), p=0.05
Log Rank p-value = 0.0483
+ Censored
Control 66 62 51 44 39 38 38
MSC 57 55 52 47 45 42 40
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC
B
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
Mortality Through 60 Days
REM 72% (38/53) vs Control 71% (29/41)
HR: 1.053; 95% CI (0.649, 1.708), p=0.8332
Log Rank p-value = 0.8206
+ Censored
Control 43 40 26 18 15 13
MSC 54 48 30 24 19 17 15
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

**FIGURE 3**

A


ITT Patients <65 Years That Received Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All ITT Patients < 65 yrs on Dexamethasone (n=74)
REM 13.8% (4/29) vs Controls 44.4% (20/45)
Treatment Effect Size: 68.9% Reduction in Death
Log Rank p-value = 0.0074
+ Censored
Control 45 42 34 30 26 25 25
MSC 29 29 27 25 25 25 25
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

B




Per Protocol Patients <65 Years That Received Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All PP Patients < 65 yrs on Dexamethasone (n=51)
REM 11.8% (2/17) vs Controls 55.9% (19/34)
Treatment Effect Size: 78.9% Reduction in Death
Log Rank p-value = 0.0043
+ Censored
Control 34 31 24 20 16 15 15
MSC 17 17 16 15 15 15 15
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

**FIGURE 4**

A


ITT Control Patients < 65 Years +/-Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All Control ITT Patients < 65 yrs +/- Dex (n=67)
Dex 44.4% (20/45) vs No Dex 36.4% (8/22)
Log Rank p-value = 0.5541
+ Censored
1 45 42 34 30 26 25 25
2 22 21 18 15 14 14 14
0 10 20 30 40 50 60
Days from Day 0 Treatment
DEXAM 1: Dexamethasone 2: No Dexamethasone

B




ITT Control Patients ≥ 65 Years +/-Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All Control ITT Patients ≥65 yrs +/- Dex (n=43)
Dex 72.4% (21/29) vs No Dex 64.3% (9/14)
Log Rank p-value = 0.815
+ Censored
1 29 28 18 12 10 8 8
2 14 12 8 6 5 5 5
0 10 20 30 40 50 60
Days from Day 0 Treatment
DEXAM 1: Dexamethasone 2: No Dexamethasone

**FIGURE 5**

A


ITT Patients <65 Years +/- Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
2
4
3
1
Log Rank p-value = 0.0669
1 45 42 34 30 26 25 25
2 29 29 27 25 25 25 25
3 22 21 18 15 14 14 14
4 29 27 26 23 21 18 17
0 10 20 30 40 50 60
Days from Day 0 Treatment
+ Censored
1: DEXAM=Dexamethasone RANDTRT=Control
2: DEXAM=Dexamethasone RANDTRT=MSC
3: DEXAM=No Dexamethasone RANDTRT=Control
4: DEXAM=No Dexamethasone RANDTRT=MSC

B



Per Protocol Patients <65 Years +/- Dexamethasone
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
2
4
3
1
Log Rank p-value = 0.0363
1 34 31 24 20 16 15 15
2 17 17 16 15 15 15 15
3 17 16 14 11 10 10 10
4 21 20 19 16 14 12 11
0 10 20 30 40 50 60
Days from Day 0 Treatment
+ Censored
1: DEXAM=Dexamethasone RANDTRT=Control
2: DEXAM=Dexamethasone RANDTRT=MSC
3: DEXAM=No Dexamethasone RANDTRT=Control
4: DEXAM=No Dexamethasone RANDTRT=MSC

**FIGURE 6-1**



C
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
+ Censored
MSC
Control
Mortality Through 60 Days
REM + Dex 14% (4/29) vs Dex 45% (20/44)
HR: 0.248; 95% CI (0.085, 0.727), p=0.011
Log Rank p-value = 0.006
+ Censored
Control 44 41 33 29 25 24 24
MSC 29 29 27 25 25 25 24
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

**FIGURE 6-2**



A
Respiratory Function Improvement: Patients < 65 Years on Dexamethasone
% of Subjects Improved from Baseline
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Day 7
Day14
Day 21
Day 30
OR: 1.1
95% CI: 0.41, 2.8
OR: 2.6
95% CI: 0.94, 7.2
OR: 2.0
95% CI: 0.72, 5.4
OR: 3.6
95% CI: 1.2, 10.7
B
Clinical Improvement: Patients < 65 Years on Dexamethasone
% of Subjects Improved from Baseline
70%
60%
50%
40%
30%
20%
10%
0%
Day 7
Day14
Day 21
Day 30
OR: 9.0
95% CI: 0.95, 84.8
OR: 1.7
95% CI: 0.62, 4.6
OR: 2.1
95% CI: 0.78, 5.5
OR: 2.9
95% CI: 1.1, 7.7
Rem-L
Placebo

**FIGURE 7**



A
Respiratory Function Improvement: Patients < 65 years
% of Subjects Improved from Baseline
80%
70%
60%
50%
40%
30%
20%
10%
0%
Day 7
OR: 1.2
95% CI: 0.57, 2.4
Day14
OR: 2.1
95% CI: 1.0, 4.5
Day 21
OR: 1.9
95% CI: 0.90, 4.1
Day 30
OR: 2.2
95% CI: 1.0, 4.7
B
Respiratory Function Improvement: Patients ≥ 65 years
% of Subjects Improved from Baseline
80%
70%
60%
50%
40%
30%
20%
10%
0%
Day 7
OR: 2.1
95% CI: 0.83, 5.1
Day14
OR: 1.1
95% CI: 0.43, 2.7
Day 21
OR: 0.94
95% CI: 0.38, 2.4
Day 30
OR: 0.75
95% CI: 0.30, 1.9
Rem-L
Placebo

**FIGURE 8**



Absence of All Cause Death at Day 90
1.0
0.8
0.6
0.4
0.2
0.0
+ Censored
MSC
Control
Mortality Through 90 Days
REM 26% (15/57) vs Control 44% (29/66)
HR: 0.517; 95% CI (0.277, 0.964), p=0.038
Log Rank p-value = 0.0347
1 66 62 51 44 39 38 38 36 36 36
2 57 55 52 47 45 42 41 41 41 41
0
20
40
60
80
Days from Day 0 Treatment
Randomized Treatment
1: Placebo
2: remestemcel-L

**FIGURE 9**



A
Distribution of Wilcoxon Scores for rank
Score
125
100
75
50
25
0
Pr > Z 0.0309
Pr > |Z| 0.0619
Control
MSC
randtrt
B
Distribution of Wilcoxon Scores for rank
Score
60
40
20
0
Pr > Z 0.0043
Pr > |Z| 0.0086
Control
MSC
randtrt

**FIGURE 10**



A
CRP
log10CRP Trt14Days_All
Marginal means
3.2
3.1
3.0
2.9
2.8
0
3
7
14
day
treat
Placebo
MSC
CRP <65 yrs
y65
CRP >65 yrs
o65
Marginal means
3.4
3.2
3.0
2.8
2.6
*
**
***

**FIGURE 11-1**



B
Ferritin
log10Ferritin Trt14Days_All
Marginal means
3.6
3.5
3.4
3.3
3.2
0
3
7
14
day
treat
Placebo
MSC
Ferritin <65 yrs
y65
Ferritin >65 yrs
o65

**FIGURE 11-2**

C



D-Dimer
log10DDimer Trt14Days_All
Marginal means
4.3
4.2
4.1
4.0
3.9
3.8
0
3
7
14
day
treat
Placebo
MSC
D-Dimer <65 yrs
y65
D-Dimer >65 yrs
o65

**FIGURE 11-3**



color2bar
FDR Up
P Up
NS
P Down
FDR Down
Effect of Age (Continuous variable)
Effect of Corticosteroids Yes vs No
Effect of Age >65 vs <65
Effect of Age >65 vs <65 In Corticosteroid Users
M2_ageEffect
M2_corticEffect
M3_ageEffectBin
M4_ageEffectBin_CortiUsers
log2FCH
Analytes
IL17C
CCL7
IL10
CXCL10
TGFA
IL2
CCL11
CXCL8
CXCL9
IL15
CSF3
IL27
CXCL12
CCL3
IL33
CCL2
VEGFA
TNFSF12
TNFSF10
CCL4
CSF1
TSLP
IL18
OLR1
TNF
IL7
CXCL11
OSM
IL4
MMP1
CCL8
IL17F
MMP12
CCL19
IL17A
CCL13
EGF
IL6
CSF2
HGF
LIF
IL1B
IFNG
IL13
FLT3LG

**FIGURE 12**



Age <65 (N=120)
Age >=65 (N=93)
Delta7vs0_Placebo
Delta7vs0_MSC
Delta14vs0_Placebo
Delta14vs0_MSC
log2(FCH)
Analytes
color2bar
FDR Up
P Up
NS
P Down
FDR Down
FLT3LG
IL17A
MMP12
IL1B
OLR1
LTA
CCL13
CCL11
IL4
IL17F
IL13
TNFSF10
IL27
MMP1
EGF
TNFSF12
CSF1
IL17C
CSF3
VEGFA
CCL3
CCL4
TGFA
CXCL12
CXCL8
IL2
CCL19
IL18
IL15
OSM
IL33
CCL2
CSF2
TSLP
IL10
HGF
CXCL11
CXCL9
IL6
CCL8
IFNG
CCL7
CXCL10

**FIGURE 13**